Merck & Co. Files 2024 Annual Report
Ticker: MRK · Form: 10-K · Filed: 2025-02-25T00:00:00.000Z
Sentiment: neutral
Topics: annual-report, pharmaceuticals, financials
TL;DR
Merck filed its 2024 10-K, check financials and strategy.
AI Summary
Merck & Co., Inc. filed its 10-K for the fiscal year ended December 31, 2024, reporting on its operations in the pharmaceutical preparations industry. The company, headquartered in Kenilworth, NJ, is a significant player in the life sciences sector. This filing provides a comprehensive overview of its financial performance and business activities for the past fiscal year.
Why It Matters
This 10-K filing provides investors and the public with a detailed look at Merck's financial health, strategic direction, and potential risks for the fiscal year 2024.
Risk Assessment
Risk Level: medium — As a large pharmaceutical company, Merck faces inherent risks related to drug development, regulatory approvals, market competition, and patent expirations.
Key Players & Entities
- Merck & Co., Inc. (company) — Filer of the 10-K
- 2024-12-31 (date) — Fiscal year end
- 2025-02-25 (date) — Filing date
- Kenilworth, NJ (location) — Company headquarters
- 2834 (industry_code) — Standard Industrial Classification for Pharmaceutical Preparations
FAQ
What was Merck & Co., Inc.'s fiscal year end?
Merck & Co., Inc.'s fiscal year end was December 31, 2024.
When was this 10-K filing submitted to the SEC?
This 10-K filing was submitted on February 25, 2025.
What is Merck & Co., Inc.'s Standard Industrial Classification code?
Merck & Co., Inc.'s Standard Industrial Classification code is 2834, which corresponds to Pharmaceutical Preparations.
Where is Merck & Co., Inc. headquartered?
Merck & Co., Inc. is headquartered in Kenilworth, NJ.
What is the SEC file number for Merck & Co., Inc.'s 10-K filing?
The SEC file number for Merck & Co., Inc.'s 10-K filing is 001-06571.
From the Filing
0001628280-25-007732.txt : 20250225 0001628280-25-007732.hdr.sgml : 20250225 20250225161911 ACCESSION NUMBER: 0001628280-25-007732 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 171 CONFORMED PERIOD OF REPORT: 20241231 FILED AS OF DATE: 20250225 DATE AS OF CHANGE: 20250225 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Merck & Co., Inc. CENTRAL INDEX KEY: 0000310158 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 221918501 STATE OF INCORPORATION: NJ FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-06571 FILM NUMBER: 25663539 BUSINESS ADDRESS: STREET 1: 2000 GALLOPING HILL ROAD CITY: KENILWORTH STATE: NJ ZIP: 07033 BUSINESS PHONE: 908-740-4000 MAIL ADDRESS: STREET 1: 2000 GALLOPING HILL ROAD CITY: KENILWORTH STATE: NJ ZIP: 07033 FORMER COMPANY: FORMER CONFORMED NAME: Merck & Co. Inc. DATE OF NAME CHANGE: 20091103 FORMER COMPANY: FORMER CONFORMED NAME: SCHERING PLOUGH CORP DATE OF NAME CHANGE: 19920703 10-K 1 mrk-20241231.htm 10-K FOR THE FISCAL YEAR ENDED DECEMBER 31, 2024 mrk-20241231 FALSE 2024 FY 0000310158 P3M http://fasb.org/us-gaap/2024#Revenues http://fasb.org/us-gaap/2024#Revenues http://fasb.org/us-gaap/2024#Revenues http://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpense http://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpense http://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpense http://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpense http://fasb.org/us-gaap/2024#ResearchAndDevelopmentExpense http://fasb.org/us-gaap/2024#ResearchAndDevelopmentExpense http://fasb.org/us-gaap/2024#ResearchAndDevelopmentExpense http://fasb.org/us-gaap/2024#ResearchAndDevelopmentExpense http://fasb.org/us-gaap/2024#RestructuringCharges http://fasb.org/us-gaap/2024#RestructuringCharges http://fasb.org/us-gaap/2024#RestructuringCharges http://fasb.org/us-gaap/2024#RestructuringCharges http://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2024#RestructuringCharges http://fasb.org/us-gaap/2024#RestructuringCharges http://fasb.org/us-gaap/2024#RestructuringCharges http://fasb.org/us-gaap/2024#RestructuringCharges http://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpense http://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpense http://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpense http://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpense http://fasb.org/us-gaap/2024#ResearchAndDevelopmentExpense http://fasb.org/us-gaap/2024#ResearchAndDevelopmentExpense http://fasb.org/us-gaap/2024#ResearchAndDevelopmentExpense http://fasb.org/us-gaap/2024#ResearchAndDevelopmentExpense http://fasb.org/us-gaap/2024#RestructuringCharges http://fasb.org/us-gaap/2024#RestructuringCharges http://fasb.org/us-gaap/2024#RestructuringCharges http://fasb.org/us-gaap/2024#RestructuringCharges http://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpense http://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpense http://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpense http://fasb.org/us-ga